Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis.
Yong Rao,Zhi-qi Kuang,Chan Li,Shi-Yao Guo,Yao-Hao Xu,Dan-Dan Zhao,Yu-Tao Hu,Bing-Bing Song,Zhi Jiang,Zhen-Huang Ge,Xi-Yuan Liu,Cheng-Dao Li,Shuo-Bin Chen,Ji-Ming Ye,Zhi-Shu Huang,Yongjun Lu +15 more
Reads0
Chats0
TLDR
Akkermansia muciniphila has been increasingly recognized for its therapeutic potential in treating metabolic disorders, including obesity, diabetes, and metabolicdysfunction-association as discussed by the authors.Abstract:
The gut bacterium Akkermansia muciniphila has been increasingly recognized for its therapeutic potential in treating metabolic disorders, including obesity, diabetes, and metabolicdysfunction-assoc...read more
Citations
More filters
Journal ArticleDOI
Gut Microbial Alterations in Diarrheal Baer's Pochards (Aythya baeri).
TL;DR: In this paper, the authors performed high-throughput sequencing of the fungal-specific internal transcribed spacer 1 (ITS-1) to detect the differences of gut mycobiota in healthy and diarrheal Baer's pochard.
Journal ArticleDOI
<i>Akkermansia muciniphila</i> plays critical roles in host health
TL;DR: A. muciniphila, an intestinal microorganism, belongs to Verrucomicrobia, one of the most abundant microorganisms in the mammalian gut as discussed by the authors , is a mucin-degrading bacterium that can colonise intestines of mammals such as humans and mice by utilising mucin as the only nitrogen and carbon source.
Journal ArticleDOI
Integrated Analysis of the Alterations in Gut Microbiota and Metabolites of Mice Induced After Long-Term Intervention With Different Antibiotics
TL;DR: It is shown that the antibiotic-induced alterations in gut microbiota contribute to host inflammatory responses through the change in metabolic status, which is likely related to the type, rather than timing of antibiotic used.
Journal ArticleDOI
Depletion of Gut Microbiota Inhibits Hepatic Lipid Accumulation in High-Fat Diet-Fed Mice
TL;DR: Gut microbiota ameliorates HFD-induced hepatic lipid metabolic dysfunction, which might be associated with genes participating in cholesterol and fatty acid metabolism in the liver.
Journal ArticleDOI
Bacteroides plebeius improves muscle wasting in chronic kidney disease by modulating the gut‐renal muscle axis
Tingting Pei,Daoqi Zhu,Sixia Yang,Rong Hu,Fujing Wang,Jiaxing Zhang,Shihua Yan,Liliang Ju,Zhu He,Zhongxiao Han,Jinhong He,Yangtian Yan,Ming Wang,Wei Xiao,Yun-ling Ma +14 more
TL;DR: In this paper , the effects of Bacteroides plebeius on protein energy consumption in rats with chronic renal failure (CKD) were investigated, and the results suggest that Bactoeides Plebeius may combat muscle atrophy through the Mystn/ActRIIB/SMAD2 pathway.
References
More filters
Journal ArticleDOI
Trimmomatic: a flexible trimmer for Illumina sequence data
TL;DR: Timmomatic is developed as a more flexible and efficient preprocessing tool, which could correctly handle paired-end data and is shown to produce output that is at least competitive with, and in many cases superior to, that produced by other tools, in all scenarios tested.
Journal ArticleDOI
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Amandine Everard,Clara Belzer,Lucie Geurts,Janneke P. Ouwerkerk,Céline Druart,Laure B. Bindels,Yves Guiot,Muriel Derrien,Giulio G. Muccioli,Nathalie M. Delzenne,Willem M. de Vos,Willem M. de Vos,Patrice D. Cani +12 more
TL;DR: Substantial insight is provided into the intricate mechanisms of bacterial regulation of the cross-talk between the host and gut microbiota and provides a rationale for the development of a treatment that uses this human mucus colonizer for the prevention or treatment of obesity and its associated metabolic disorders.
Journal ArticleDOI
Mechanisms of NAFLD development and therapeutic strategies
TL;DR: Understanding of pathogenic mechanisms and clinical features of NAFLD is driving progress in therapeutic strategies now in clinical trials and the emerging targets for drug development that involve either single agents or combination therapies intended to arrest or reverse disease progression are discussed.
Journal ArticleDOI
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines:
TL;DR: The following guidelines are excerpted (as permitted under the Creative Commons Attribution License (CCAL), with the knowledge and approval of PLoS Biology and the authors) from Kilkenny et al.
Journal ArticleDOI
NAFLD: A multisystem disease
TL;DR: A narrative review focuses on the rapidly expanding body of clinical evidence that supports the concept of NAFLD as a multisystem disease and the factors linkingNAFLD with other extra-hepatic chronic diseases, such as T2DM, CVD, cardiac diseases and CKD.
Related Papers (5)
Dietary betaine prevents obesity through gut microbiota-drived microRNA-378a family.
Jingjing Du,Peiwen Zhang,Jiang Luo,Linyuan Shen,Shunhua Zhang,Hao Gu,Jin He,Linghui Wang,Xue Zhao,Mailing Gan,Liu Yang,Lili Niu,Ye Zhao,Qianzi Tang,Guoqing Tang,Dongmei Jiang,Yanzhi Jiang,Mingzhou Li,Anan Jiang,Long Jin,Jideng Ma,Surong Shuai,Lin Bai,Jinyong Wang,Bo Zeng,De Wu,Xuewei Li,Li Zhu +27 more